By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Foundation Medicine's today said that its genomic tests will be used by biopharmaceutical company Celgene for clinical trials of its anti-cancer drug candidates.

Foundation's test, which is under development, will be used to hasten faster recruitment of target patient populations and for broad genetic characterization of trial enrollees in order to identify patients most likely to respond to Celgene's drug candidates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

ScienceInsider reports that a new security policy at the US Food and Drug Administration may prevent foreign nationals from working there.

WBUR in Boston looks into Orig3n's genetic fitness assessments to find more research is needed.

Cleveland.com reports that getting a DNA profile removed from a law enforcement database can be tricky.

In PNAS this week: de novo mutations contribute to non-syndromic craniosynostosis, fungal tree of life, and more.